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A genomic screen for genes upregulated
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Aberrant hypermethylation of gene promoters is a major mechanism associated with inactivation of tumor-suppres-
sor genes in cancer. We previously showed this transcriptional silencing to be mediated by both methylation and his-
tone deacetylase activity, with methylation being dominant. Here, we have used cDNA microarray analysis to screen
for genes that are epigenetically silenced in human colorectal cancer. By screening over 10,000 genes, we show that
our approach can identify a substantial number of genes with promoter hypermethylation in a given cancer; these are
distinct from genes with unmethylated promoters, for which increased expression is produced by histone deacetylase
inhibition alone. Many of the hypermethylated genes we identified have high potential for roles in tumorigenesis by
virtue of their predicted function and chromosome position.We also identified a group of genes that are preferentially
hypermethylated in colorectal cancer and gastric cancer. One of these genes, SFRP1, belongs to a gene family; we
show that hypermethylation of four genes in this family occurs very frequently in colorectal cancer, providing for (i) a
unique potential mechanism for loss of tumor-suppressor gene function and (ii) construction of a molecular marker
panel that could detect virtually all colorectal cancer.
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Introduction
A frequent epigenetic change in cancer involves aberrantly
hypermethylated CpG islands in gene promoters, with loss of
transcription of the genes1. Recognition of this promoter hyper-
methylation has fostered a growing effort to screen the cancer
genome to identify such loci. These search strategies, including
the identification of hypermethylated CpG islands in regions of
high-frequency loss of heterozygosity2 and throughout the
genome3–5, have all proven useful for identifying hypermethy-
lated CpG islands that are tumor-specific. However, each strategy
is hindered by one or more factors: (i) the identification of sites
that are not associated with gene promoters, (ii) the potential
bias of methylation-sensitive restriction sites for CpG island sub-
sets, (iii) the lack of utilized restriction sites in many islands and
(iv) the need to laboriously search for nearby genes once the
altered locus is identified.
We describe a new microarray-based strategy that combines
gene expression status and epigenetic regulation. The approach is
based upon our recent observation that silencing of hypermethy-
lated genes in cancer is dependent on both methylation of dense
CpG islands and histone deacetylase (HDAC) activity6. We show
that this procedure robustly identifies new genes for which tran-
scriptional repression might mediate tumorigenesis and helps
define the nature of gene promoters controlled by either a com-
bination of methylation and HDAC activity or only by HDAC.
Our gene screening technique has led to the identification of
gene hypermethylation events that cluster within specific tumor
types, and can simultaneously involve several members of a sin-
gle gene family.
Results
Microarray analysis and categorization of
upregulated genes
We used cDNA microarray technology to identify genes upregu-
lated in the colorectal cancer (CRC) cell line RKO, after cells were
treated with low-dose 5-aza-2′ deoxycytidine (DAC), which min-
imally blocks DNA methylation, and trichostatin A (TSA) to
inhibit HDAC. In our first study with this drug combination, we
showed that the low dose of DAC used and the short treatment
time for the cells resulted in only a few alleles being demethy-
lated, and these alleles may have led to the upregulation of gene




































microarray screen. Indeed, we initially failed to detect control
genes arrayed on our filters, which were known to be synergisti-
cally reactivated by the drug combination, in the cell line
studied6,7. We therefore increased the sensitivity of our screen by
carrying out an initial cDNA subtraction step between mock-
treated and DAC- and TSA-treated RKO cells, using the mock-
treated cells as the driver and the drug-treated cells as the tester
populations. The PCR product after the second round of sub-
traction was then used as a probe for microarray hybridization.
Of the four control genes (MLH1, CDKN2A, TIMP3, PTGS2)
arrayed on the filters that were known to be methylated in RKO
cells, we could not detect MLH1 re-expression; however, we suc-
cessfully detected, as validated by PCR, the other three control
genes (Fig. 1a). For unknown genes, we selected those that
showed no expression in the mock filter (genes having the same
intensity as empty spots when probed with non-subtracted
cDNA from mock-treated cells) and showed detectable expres-
sion after probing with the subtraction products from mock-
treated and drug-treated cells (Fig. 1a). We analyzed these genes
by semi-quantitative RT–PCR in cells subjected to mock treat-
ment and DAC alone, TSA alone, or a combination of the two
drugs. Of a total of 10,814 genes examined by subtraction
microarray, 74 were upregulated by treatment with DAC and/or
TSA. We divided these genes into two groups. Group 1 (n = 51)
genes showed no change in expression with TSA alone, minimal
increase in expression after low-dose DAC alone, and stronger
induction by the combined DAC and TSA treatment (Table 1 and
Fig. 1b). Group 1 genes could be subdivided into two groups:
group 1a genes (n = 24) are completely inactivated in mock cells,
whereas group 1b genes (n = 27) show some basal expression
detected by RT–PCR (Fig. 1b). Group 2 genes (n = 23), by con-
trast, are upregulated in expression by TSA alone and have a vari-
able initial expression or response to DAC alone (Fig. 1b).
Of all of the non-EST (expressed sequence tags) genes (Table 1),
56 had known chromosomal positions. We were able to identify a
putative transcription start site for 46 of the genes by searching all
available genome databases. We were also able to identify 5′ CpG
islands (GC content > 60%, ratio of CpG to GpC > 0.6 and mini-
mum length 200 bp)8 for 27 of the 56 genes. Failure to find CpG
islands in the putative upstream regions of the remaining genes
could indicate either that a CpG-rich proximal promoter was not
present, that a CpG island contained a control region located fur-
ther upstream than available genomic data allowed us to analyze or
that the region identified was not the true transcription start site.
Methylation analysis of 5′ CpG islands
We analyzed the methylation status of the CpG islands by using
bisulfite-PCR in combination with methylated CpG site–specific
restriction enzymes9 and methylation-specific PCR (MSP)10. We
compared the results with the gene expression status. All 12 of
the group 1a genes (including 3 positive control genes) with
identifiable 5′ CpG islands contained dense methylation of these
regions in RKO cells (Fig. 2a,b and Table 1) and showed no basal
expression detectable by RT–PCR (Fig. 1b). Of the five group 1b
genes, for which we identified 5′ CpG islands, three showed par-
tial methylation in these regions (Table 1), in agreement with
their low basal expression levels (Fig. 1b). However, the other two
genes did not show any methylation. None of the ten group 2
genes, whether they showed basal expression or not, showed any
methylation of their 5′ CpG islands (Fig. 2c,d and Table 1).
Methylation and expression of group 1a genes
We first studied the methylation status and expression of group
1a genes in a series of eight CRC cell lines (Figs 2b and 3). We
found hypermethylation of the genes SFRP1, SEZ6L, PCDH8
and FOLH1 in all CRC lines investigated. Of the eight lines, five
showed total or predominant methylation of KIAA0786. The
gene CXX1 is of particular interest, because it is located on the
X chromosome and is normally inactivated and methylated on
one allele and active and unmethylated on the other in female
cells. However, only methylated or predominantly methylated
CXX1 alleles were found in five of the eight CRC lines, includ-
ing RKO, which, except for HT29, were all derived from males
with cancer. SNRPN is also unusual in that it is known to be
maternally imprinted in humans and to have a hypermethy-
lated CpG island in the promoter region of the silenced allele.
Thus, as expected, normal peripheral blood lymphocytes
showed partial methylation of the CpG island around the tran-
scription start site11. However, RKO, HCT116 and SW480 cells
showed complete methylation and lack of basal expression
article
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Fig. 1 Microarray analysis and catego-
rization of genes by semi-quantitative
RT–PCR. a, Examples of subtraction
microarray hybridization in RKO.
Paired results of microarrays probed
with non-subtracted RKO cDNA from
mock-treated cells and the same array
probed with post-subtraction cDNA
from combination-treated cells are
shown. Yellow circles indicate genes
appearing only with the subtraction
probe. b, Representative results of
semi-quantitative RT–PCR of RKO cells.
Group 1a are genes without expression
in mock- (lane 1) and TSA- (lane 5)
treated RKO cells, upregulated after
low-dose DAC treatment (lane 3) and
showing greater re-expression after
the combination of DAC and TSA (lane
7). Group 1b genes show similar pat-
terns, although basal expression was
detected in mock cells. Group 2 genes
can be upregulated by TSA alone,
whereas their basal expression and
upregulation with DAC vary among
genes. The gene GAPD serves as a posi-
tive control to ensure cDNA quality and
loading accuracy. The accession num-
ber for the EST is W46439 (see Table 1).
group 1a group 2
group 1b
RT + – + + + –
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Fig. 2 Methylation analysis of group 1a and group 2 genes in a series of CRC cell lines. a, Schematic representations of 5′ regions of group 1a genes. Black bars
indicate first exons. Vertical bars indicate CpG sites. Regions analyzed by MSP are shown by black bars below the CpG sites. b, Examples of MSP analysis in a series
of CRC cell lines. Bands in ‘M’ lanes are PCR products for methylation-specific primers, and those in ‘U’ lanes are products with unmethylated-specific primers.
Peripheral blood lymphocytes (PBL) and in vitro methylated DNA (IVD) serve as negative and positive controls, respectively. c, Schematic representations of 5′
regions of group 2 genes. First exons, CpG sites and regions analyzed by MSP are indicated. d, MSP analysis in a series of CRC cell lines.
(data not shown). S100A10 and TIMP2 methylation was seen
only in RKO cells. Notably, each of the above genes lacked basal
expression in methylated lines, which was restored by DAC
(Fig. 3). We found, unexpectedly, that KIAA0786 was not
basally expressed in SW480 cells, despite lack of methylation,
and yet was reactivated by DAC.
Methylation of group 1a genes in primary CRC tissues
We next investigated the methylation status of group 1a genes in
primary colon cancers and normal colon tissues. We found a
high frequency (17/20) of SFRP1 methylation in primary CRC
samples, but did not find methylation in 6 of 17 normal tissues
from the same individuals with the tumors and from 3 individu-
als whose tumors showed no methylation (Fig. 4). In 11 individ-
uals, SFRP1 methylation occurred in both tumors and normal
cells, but tumors showed stronger methylation signals (Fig. 4).
We found no methylation of SFRP1 in normal colon tissues from
two individuals without CRC (data not shown).
The genes SEZ6L and KIAA0786 also showed a high frequency
of hypermethylation in primary CRC (13 of 20 and 8 of 20
affected individuals, respectively). These genes showed no
methylation in normal colon of individuals whose tumors har-
bored no methylated genes, and some methylation in normal
colon of individuals with tumors that contained methylated
genes (2 of 13 and 4 of 8 individuals, respectively). The tumors
showed stronger methylation signals than the normal tissues
(Fig. 4). As expected, all tissue samples, including normal colon
mucosa from females, showed partial methylation of CXX1.
However, 3 of 14 males showed CXX1 methylation in a tumor-
specific manner (Fig. 4). We did not find methylation of S100A10
and TIMP2 in any primary CRC sample (Fig. 4). Notably,
FOLH1 and PCDH8 were equally methylated in every CRC sam-
ple and normal counterpart (data not shown).
Methylation patterns of group 1a genes link CRC and
gastric cancers
Our findings suggested that SFRP1, SEZ6L, CXX1, KIAA0786,
S100A10 and TIMP2 might influence tumor development and
progression. We therefore studied these genes in tumor cell
lines of other types of cancer. A pattern of tumor profiling
emerged: complete hypermethylation of SFRP1, SEZ6L,
LPPH1 and CXX1 was common in CRC and gastric cancers,
but only partial or no methylation was seen in all other types of
cancer studied (Fig. 5). We found exceptions to this pattern for
SFRP1. This gene has been shown to induce apoptosis in a
breast cancer cell line, MCF7, which did not express the gene
in the basal state12. We found complete methylation of the
CpG island region in this cell line, as well as in MDA MB231
breast cancer cells and two of four prostate cancer cell lines
studied (Fig. 5).
Methylation and expression of SFRP family members
So far, five SFRP genes have been identified. We found that four
of these five genes have dense CpG islands around their first
exons (Fig. 6a). The gene without a CpG island, SFRP3, was
expressed basally in all seven CRC cell lines tested (data not
shown). However, the other four SFRP genes are all hypermethy-
lated with a high frequency in CRC cell lines; this hypermethyla-
tion is associated with a lack of basal expression, which is
restored by DAC treatment (Fig. 6b,c).
article




































Table 1 • Genes upregulated by DAC and TSA treatment in RKO cells
Group 1a
Acc no.a Gene name Symbol Location CpG islandb Methylationc
R80217 prostaglandin-endoperoxide synthase 2 PTGS2d 1q25.2–q25.3 yes yes
(prostaglandin G/H synthase and cyclooxygenase)d
AA877595 cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)d CDKN2Ad 9p21 yes yes
AA099153 tissue inhibitor of metalloproteinase 3 TIMP3d 22q12.3 yes yes
(Sorsby fundus dystrophy, pseudoinflammatory)d
AA444051 S100 calcium-binding protein A10 S100A10 1q21 yes yes
N32514 secreted frizzled-related protein 1 SFRP1 8p12–p11.1 yes yes
W72596 CAAX box 1 CXX1 Xq26 yes yes
H29013 seizure-related gene 6 (mouse)-like SEZ6L 22q11.2–12.1 yes yes
W74533 latrophilin KIAA0786 1p31.1 yes yes
AA486280 tissue inhibitor of metalloproteinase 2 TIMP2 17q25 yes yes
H29216 protocadherin 8 PCDH8 13q14.3–q21.1 yes yes
N64840 folate hydrolase (prostate-specific membrane antigen) 1 FOLH1 11p11.2 yes yes
AI017332 human SNRPN mRNA, 3′ UTR, partial sequence SNRPN 15q12 yes yes
N54793 pregnancy specific β-1-glycoprotein 6 PSG6 19q13.2 no
H87471 kynureninase (L-kynurenine hydrolase) KYNU 2p23.3–q14.3 no
AA001432 laminin, α3 (nicein (150 kD), kalinin (165 kD),BM600 (150 kD), epilegrin) LAMA3 18q11.2 no
AA034939 laminin, alpha 2 (merosin, congenital muscular dystrophy, LAMA2) LAMA2 6q22–q23 no
AI298976 small inducible cytokine subfamily C, member 1 (lymphotactin) SCYC1 1q21–q25 no
AA291484 cytochrome P450, subfamily IVB, polypeptide 1 CYP4B1 1p34–p12 no
R62603 Collagen, type VI, α3 COL6A3 2q37 no
T73558 deoxyribonuclease I-like 3 DNASE1L3 3p21.1–3p14.3 no





Acc no.a Gene name Symbol Location CpG islandb Methylationc
AA173290 homeo box A1 HOXA1 7p15.3 yes partial
AA935273 GRO3 oncogene GRO3 4q21 yes partial
AA256304 distal-less homeobox 7 DLX7 17q21.33 yes partial
H17115 stromal antigen 3 STAG3 7 yes no
AA454880 heterogeneous nuclear ribonucleoprotein D HNRPD 4q21.1–q21.2 yes no
(AU-rich element RNA-binding protein 1, 37 kD)
AA496149 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) HMGCS2 1p13–p12 no
AA176491 myogenic factor 6 (herculin) MYF6 12q21 no
H16793 chromosome 8 open reading frame 4 C8orf4 8p11.2 no
H10079 KIAA0751 gene product 8 no
H59614 similar to putative insulin-like growth factor II associated protein 11p15.5 uk
AA457731 SNARE protein YKT6 6 uk
AA419251 interferon induced transmembrane protein 1 (9-27) IFITM1 11 uk
N48178 KIAA0403 protein 6 uk
AA027147 hypothetical protein MGC3040 3 uk
H18646 hypothetical protein FLJ10697 10 uk













Acc no.a Gene name Symbol Location CpG islandb Methylationc
AA425908 partner of RAC1 (arfaptin 2) POR1 11p15 yes no
AA405717 muscleblind (Drosophila melanogaster)-like MBNL 3 yes no
AA916906 TNFRSF1A-associated via death domain TRADD 16q22 yes no
AA404394 for protein disulfide isomerase-related PDIP 3 yes no
AA489678 RAD23 (S. cerevisiae) homolog B RAD23B 3p25.1 yes no
AA447514 ribosomal protein L13 RPL13 16q24.3 yes no
AA071330 guanine nucleotide binding protein (G protein), GNAI2 3p21 yes no
α-inhibiting activity polypeptide 2
AA669126 protein phosphatase 1, regulatory (inhibitor) subunit 12A PPP1R21A 12q15–q21 yes no
R38619 fucose-1-phosphate guanyltransferase FPGT 1 yes no
AA055503 tripartite motif-containing 32 TRIM32 9q32–q34.11 yes no
T66981 egf-like module containing mucin-like, hormone receptor-like sequence 1 EMR1 19p13.3 no
AA480906 protein kinase C binding protein 1 PRKCBP1 20q12 no
N45318 phosphoglycerate mutase 2 (muscle) PGAM2 7p13–p12 no
N30096 glutathione S-transferase A3 GSTA3 6p12 no
AA427733 advillin ADVIL 12 no
N92901 fatty acid binding protein 4, adipocyte FABP4 8q21 no
T60149 hypothetical protein FLJ13449 13 uk
AA453578 human DNA sequence from clone RP11-3J10 on chromosome 9–12-13.3 9p12–p13.3 uk





aGenBank accession number. bYes: CpG island was found around presumed transcription start site or near upstream region; no: no CpG island was found around
presumed transcription start site or near upstream region; uk: upstream genomic sequence is unknown. cYes: fully methylated; partial: partially methylated; no:
no methylation. dPositive control genes.
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We analyzed methylation of
these genes in primary CRC tis-
sues (n = 124). The genes are
not hypermethylated in normal
colon, except for trace methyla-
tion of SFRP2 in an individual
who has a colon cancer in
which this gene is hypermethy-
lated. In addition, normal
colon and cell lines derived
from other tissues express the
genes in the absence of promoter methylation (Fig. 6c). However,
we found hypermethylation of all three genes in primary CRC
tumors (Fig. 6d). The frequencies differ in this large analysis,
which includes expanded data for SFRP1 (SFRP1, 118/124,
95.1%; SFRP2, 111/124, 89.5%; SFRP4, 36/124, 29.0%; and
SFRP5, 73/124, 58.9%). Notably, 24.1% of affected individuals
(30/124) show methylation of all four SFRP genes with CpG
islands, and at least one of the four is methylated in 123 of 124
(99.2 %) of the tumors (Fig. 7).
These data show that logical mining of the initial microarray
data can markedly extend the gene discovery consequences. The
findings also reveal the involvement in epigenetic silencing of a
gene family which, in CRC, could abrogate a block to WNT
oncogene activity. To our knowledge, this hypermethylation of a
single gene family provides the highest molecular marker cover-
age yet for a common human cancer13.
Discussion
Our previous studies suggest that the transcriptional silencing of
hypermethylated genes in cancer cells depends on synergy
between the methylation and the activity of HDACs, with methy-
lation having the dominant effect6. Our findings seem to validate
this concept concerning the nature of chromatin associated with
such genes and to provide a strategy with high efficiency for
identifying genes with high potential for a role in tumorigenesis.
From the standpoint of tran-
scriptionally repressive chro-
matin, the strategy we have
used has provided information
about the promoters of genes
with various responses to
inhibitors. Our findings with
respect to group 1a genes con-
firm that densely methylated
genes will not re-express if
exposed to HDAC inhibition
alone. In contrast, the results
for group 2 genes indicate that
those genes that do re-express
or have upregulated expression
after HDAC inhibition alone
lack promoter methylation,
even when CpG islands are
present in their 5′ regions. Our
study also identifies genes that were upregulated after treatment
of cells with DAC, despite the fact that their promoters seemed to
be unmethylated. Similar findings have recently been reported14.
Perhaps methylation of upstream genes, such as those encoding
transcription factors, could secondarily result in activation of
these genes. Another possibility, however, is that inhibitors of
DNA methyltransferases, such as DAC, might affect these pro-
teins in ways other than simply blocking their methylating capac-
ities. Recent studies showed that DNA methyltransferases have
the potential to repress transcription independently of their
methylating activities15–19, both directly and through interaction
with HDACs and other corepressor proteins.
That our approach begins with established cell lines could lead
to bias toward detection of genes that are either altered only in
culture but not in primary tumors, or for which promoter hyper-
methylation is not tumor-specific. Excessive CpG island hyper-
methylation in cancer cell lines, compared with primary cancer
tissues, has been described20. However, analysis of paired pri-
mary tumors and normal tissues suggests that our method effi-
ciently identifies genes for which altered expression is associated
with hypermethylated 5′ CpG islands in primary as well as cul-
tured cells. Seven of the 12 genes detected by the microarray
approach, CDKN2A, COX2, TIMP3, SEZ6L, SFRP1, KIAA0786
and CXX1 were methylated specifically in primary tumors or
only in regions of normal colon from individuals with CRC who
Fig. 3 RT–PCR analysis in various CRC
cell lines. For SEZ6L and SFRP1, hepa-
tocellular carcinoma cell lines with-
out methylation (Hep3B, SNU182 and
PLC/PRF/5) are also shown, as exam-
ples of cells where these genes are
unmethylated. The gene GAPD serves
as a positive indicator for RNA quality
and loading. ‘DAC’ indicates cell lines
























































































































































































































Fig. 4 MSP analysis of group 1a genes in primary CRC tissues (T) and normal colon mucosa (N) from the same affected
individuals. Cases 1, 5, 6 and 7 are tumors from affected males; the others are from females. Bands in ‘M’ and ‘U’ lanes
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showed methylation of those genes. Another gene, TIMP2,
although not methylated in normal colon, primary CRCs or
peripheral blood lymphocytes, has subsequently proven to be
very frequently hypermethylated in malignant lymphomas (data
not shown). In addition, SNRPN, an imprinted gene, was methy-
lated in the promoter of the silenced allele. Two genes were
methylated in both normal colon and primary CRCs. Only
S100A10 has not been found to be methylated in primary tissues
in our study so far, but our analysis is not extensive and this gene
has been reported to be downregulated in prostate cancer21.
Our microarray-based approach identified a large number
of genes that are hypermethylated in a tumor-specific man-
ner. Some genes, such as SFRP1, were found to be methylated
in some, but not all, normal colon mucosa tissues from indi-
viduals with, but not without, CRC. This methylation of
genes in normal tissues could reflect a ‘field effect’, in which
pre-malignant changes are found over a broad region of the
colon, or could indicate a tendency for certain CpG islands to
become methylated with age in normal colon, as has been
found for a group of genes frequently hypermethylated in
CRC22. The field effect seems more likely, as the age of indi-
viduals with no methylation in normal tissues ranged from
53 to 64 years, and one 46-year-old individual showed methy-
lation in both normal and tumor tissues.
One advantage of this approach is that most of the genes we
identified have known properties or implied functions that are







































































Fig. 5 Summary of MSP analyses of six genes from group 1a in a series of
human cancer cell lines of various origins. Gene names are indicated at the
top, and cell line names are indicated on the left. Closed boxes indicate full
methylation; gray boxes and open boxes indicate partial methylation and
no methylation, respectively. ND, not determined (because of lack of ampli-
fication in MSP).
















































































MU M U M U M U M U M U M U M U
N T N T N T N T
case S11 case S22 case S23 case S05
U M U M U M U M
N T N T






100 bp exon 1












Fig. 6 Methylation and expression analysis of the SFRP genes. a, Schematic rep-
resentations of 5′ regions of SFRP2, 4 and 5. The large black bars indicate first
exons. Vertical bars indicate CpG sites. Regions analyzed by MSP are shown as
black bars below the CpG sites. b, Examples of MSP analysis in a series of cell
lines. Bands in ‘U’ and ‘M’ lanes are as indicated in Figs 2 and 3. MSP analyses
for cell lines PCL/PRF/5 and SNU182, and of normal peripheral blood lympho-
cytes (PBL), are shown as controls for unmethylated promoters; the in vitro
methylated DNA IVD reactions are shown as positive controls for partially
methylated promoters. c, RT–PCR analysis of the SFRP genes. PLC/PRF/5,
SNU182, two normal colon mucosa samples and PBL are shown as positive con-
trols for expression of each gene in a setting of a non-methylated promoter
region. ‘DAC’ indicates PCR for cell lines treated with 5 µM DAC. d, MSP analy-
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many genes in the other groups, are located in chromosomal
regions known to undergo frequent loss of heterozygosity in
cancers, including SFRP1 at chromosome 8p12, SEZ6L at 22q11
and TIMP2 at 17q25 (Table 1). In addition, many of the genes
identified encode components of pathways that have been
implicated in cancer. For example, among the group 1a genes,
SFRP1 antagonizes Wnt oncogene signaling23, and breast cancer
cells transfected with SFRP1 showed increased sensitivity to pro-
apoptotic stimuli12. Underexpression of SFRP1 has been
reported in the majority of breast carcinomas24,25. Expression of
mouse SEZ6 and rat latrophilin is limited to brain; however,
their human homologs (SEZ6L and KIAA0786) were identified
in frequently deleted regions in lung and breast cancers, respec-
tively, although their functions in humans remain unclear26,27.
TIMP2 is a member of the tissue inhibitor of matrix metallopro-
tainase (TIMP) family; another member, TIMP3, is known to be
frequently inactivated by hypermethylation in various malig-
nancies28. The S100A10 protein, also termed annexin II light
chain or p11, forms a heterotetrameric complex with another
calcium-binding protein, annexin II heavy chain (p36)29. A
recent study reported frequent loss of p36 and p11 protein
expression in prostate cancers and suggested that methylation
could be responsible for the silencing of p36 (ref. 21). CXX1 is a
putative prenylated protein, but its function remains unclear30.
SNRPN is located on 15q11-q13, a region that is implicated in
Prader-Willi syndrome and Angelman syndrome, and is
thought to be involved in pre-mRNA splicing31.
The genes FOLH1 and PCDH8 also have notable characteris-
tics. Folate metabolism affects DNA methylation, and recent
reports suggested that one of the folate metabolic enzymes,
methylenetetrahydrofolate reductase, may affect susceptibility to
human malignancies32,33. The FOLH1 protein is involved in
folate uptake and may have a role in DNA methylation in can-
cers34. The gene PCDH8 encodes a member of a cell–cell adhe-
sion molecule family35 for which loss of function is known to be
important in invasion and metastasis. However, these two genes
did not show tumor-specific or tumor-predominant methyla-
tion. The FOLH1 protein was originally characterized as a
prostate-specific membrane antigen, is strongly expressed in
prostate cancers34 and has not been studied in colorectal tumors.
In normal tissues, PCDH8 is expressed exclusively in fetal and
adult brain35. Thus, methylation of FOLH1 and PCDH8 might
be a tissue-specific phenomenon that seems to be related to gene
expression, as these genes are silent in CRC cell lines and treat-
ment of these cells with DAC leads to re-expression.
One unexpected finding is the frequent hypermethylation of
many genes involved in gastrointestinal tumorsin particular,
hypermethylation of the SFRP gene family. This finding raises
several possibilities. First, a common defect in chromatin consti-
tution may bias several genes, and particularly a family of related
genes, toward epigenetic silencing in association with promoter
hypermethylation. Second, all of the SFRP genes are thought to
counter WNT/frizzled signaling23,36–38; loss of function of these
genes could represent abrogation of an entire tumor-suppressor
pathway. For example, mutations of APC are common in colon
cancer and could lead to constitutive WNT pathway action39,40.
Our initial data indicate that APC mutations are frequent
throughout CRC tumors with all combinations of hypermethyla-
tion of the SFRP genes (data not shown). However, APC has
additional postulated functions41; thus, loss of inhibition of
WNT activity through other mechanisms indicates a new func-
tional pathway important to colorectal tumorigenesis.
Our approach could allow the identification of the entire spec-
trum of genes silenced by epigenetic mechanisms in cancers. Our
finding that the methylation patterns for the newly identified
genes map with the specific cancer type initially screened and a
related tumor type (Fig. 5) underlines the importance of pro-
moter hypermethylation for profiling of human cancers.
Notably, CRC and gastric tumors have another previously
demonstrated hypermethylation pattern. These are among the
few kinds of tumors that show the microsatellite instability phe-
notype due to loss of mismatch repair function; in each case, the
link is a hypermethylation event involving the promoter of
MLH1 (ref. 1). Thus, panels of such markers have potential for
facilitating basic studies of the pathways that regulate tumorigen-
esis. Moreover, the mechanisms involved in linking the hyperme-
thylated genes that we have identified in a single colon cancer line
to gastrointestinal tumors are important to explain at a biological
level. Our findings further demonstrate how a limited number of
hypermethylated genes may be used to compose comprehensive
marker panels for sensitive detection of specific types of human
cancer, and suggest that our technique may be especially suited























































































































































Fig. 7 Summary of MSP analyses of the SFRP genes in 124 primary CRC samples.
Gene names are indicated at the top. Each row represents a primary CRC tumor.
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Methods
Cell culture and tissue samples. We cultured cell lines in RPMI 1640 or
Minimal Essential Medium (GIBCO BRL) supplemented with 10% fetal
bovine serum. Tissue samples of colorectal cancer and normal colon
mucosa were all from specimens obtained at the time of clinically indicated
surgical procedures.
DAC and TSA treatment and RNA preparation. We treated RKO cells with
DAC (Sigma) and TSA (Wako) as described previously6. Briefly, the treat-
ment consisted of DAC (200 nM) for 48 h, with drug and medium replaced
24 h after the beginning of treatment, followed by addition of TSA, to a final
concentration of 300 nM from a 1.5-mM ethanol-dissolved stock, for a fur-
ther 24 h. We also treated cells with mock, DAC alone and TSA alone by using
the same volumes of PBS and/or ethanol, and/or same amount of the drugs.
We also treated some CRC cell lines for RT-PCR analysis, to assess more
robust levels of gene expression, with 5 µM of DAC for 72 h, replacing drug
and medium every 24 h. We extracted total RNA used for microarray analysis,
cDNA subtraction and RT–PCR by using the TRIZOL Reagent (Gibco/BRL).
cDNA subtraction. Before cDNA subtraction, we isolated poly(A)+ RNA
from total RNA by using the Message Maker Reagent Assembly kit (Gib-
co/BRL). We carried out cDNA subtraction with a combination-treated
RKO cell line as the tester, and mock treated cells as the driver, by using the
PCR-Select cDNA Subtraction Kit (Clontech). We digested synthesized
cDNA with RsaI and ligated tester cDNA to adaptors included in the kit.
After hybridization, we amplified the subtracted cDNA by using the
Advantage cDNA PCR kit (Clontech).
Microarray analysis. We carried out microarray analysis using the Mam-
malian GeneFilters Microarrays system (Research Genetics). We produced
filters for approximately 5,000 of the genes analyzed in the Johns Hopkins
Comprehensive microarray core, and we also purchased filters for another
5,000 genes (Human GeneFilters Microarrays Release II) from Research
Genetics. We analyzed a total of 10,814 genes and ESTs. We hybridized the
filters according to the manufacturer’s recommendation. Briefly, we
reverse-transcribed and labeled 5 µg of total RNA using oligo (dT)12–18
primer and [33P]dCTP with Superscript II reverse transcriptase
(Gibco/BRL). We hybridized the filters for 12–18 h. We analyzed the data
thus obtained by using the PSCAN program (National Institutes of
Health). For subtraction–microarray analysis, we labeled the second PCR
product from cDNA subtraction by using the Multiprime DNA Labeling
System (Amersham) with 33P. We carried out hybridization and data analy-
sis as described above. We repeated microarray analysis independently at
least three times for each condition and compared results for probing the
arrays with cDNA for total RNA from mock-treated cells to those for
hybridizations with subtraction PCR products.
Semi-quantitative RT–PCR. We reverse-transcribed total RNA (2 µg)
treated with DNase I (Ambion) for single-stranded cDNA using oligo
(dT)12–18 primer with Superscript II reverse transcriptase (Gibco/BRL).
We carried out PCR reactions in a volume of 50 µl containing 1× PCR
buffer (Gibco/BRL), 1.5 mM of MgCl2, 0.3 mM of dNTP, 0.25 µM of each
primer and 2 U of Taq polymerase (Gibco/BRL). We used 100 ng of cDNA
for PCR amplification, and we amplified all of the genes with multiple
cycle numbers (20 cycles to 35 cycles) to determine the appropriate condi-
tions for obtaining semi-quantitative differences in their expression levels.
We carried out the RT–PCR analyses in Fig. 3 with 35 cycles. We also car-
ried out PCR with GAPD (25 and 28 cycles) to ensure cDNA quality and
loading accuracy. Primer sequences are available upon request.
Methylation analysis. We carried out bisulfite modification of genomic DNA
as described previously10. We studied methylation status with PCR analysis of
bisulfite-modified genomic DNA, using two procedures. First, all genes inves-
tigated were analyzed by bisulfite-PCR, followed by digestion with several
methylated CpG site-specific restriction enzymes (COBRA), as described9.
The second analysis used MSP for all genes analyzed in several cancer cell lines
and tissue samples, as described10. We designed all of the bisulfite PCR and
MSP primers according to genomic sequences around presumed transcrip-
tion start sites of investigated genes. Primer sequences and PCR conditions
for methylation analysis are available upon request.
Methylation and expression analysis of the SFRP genes. We carried out
methylation analysis of SFRP2 and SFRP4 by using three different MSP
primer pairs to cover the 5′ CpG islands of each gene. For SFRP5 methylation
analysis, we used two different MSP primer pairs. For SFRP2 RT–PCR, we
designed sense and antisense primers to amplify exons 2 and 3, respectively.
We designed RT–PCR primers for SFRP4 to amplify exons 2 and 5. RT–PCR
primers for SFRP5 were designed to amplify exons 2 and 3. For each gene, we
used the MSP primer pair that best assessed the methylation status of the
gene with respect to the expression data in cell lines in Fig. 6; we also used
these primers for analysis of primary CRC tissues. Primer sequences for MSP
and RT–PCR are available upon request.
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